

Supplemental breast cancer screening: Fowler provides perspective on the advantages and challenges of molecular screening approaches, such as breast-specific γ -imaging, in women with increased breast cancer risk and previews a related article in this issue of *JNM*. **Page 661**

c-MET visualization: Pool and colleagues look at promising approaches and tracers in development for PET and PET/CT imaging targeting c-MET-expressing tumors and introduce an article on this topic in this issue of *JNM*. **Page 663**

^{90}Y microspheres for colorectal metastases: Hickey and colleagues report on survival and safety outcomes in a large cohort of patients with colorectal liver metastases treated with glass-based ^{90}Y microspheres. **Page 665**

^{68}Ga -alfatide II in NSCLC and TB: Kang and colleagues compare the diagnostic potential of this new RGD-based angiogenesis tracer with that of ^{18}F -FDG in PET/CT differentiation of non-small cell lung cancer from lung tuberculosis. **Page 672**

BSGI detection of breast cancer: Brem and colleagues look at increases in disease detection when breast-specific γ -imaging is used as an adjunct to mammography in women at increased risk for breast cancer. **Page 678**

Thyroid cancer and breast cancer risk: Lin and colleagues investigate the risk of breast cancer in patients with thyroid cancer and include analyses of the effects of ^{131}I treatment or non-treatment on this risk. **Page 685**

PET and esophageal cancer response: van Rossum and colleagues determine whether subjective and quantitative assessment of baseline ^{18}F -FDG PET can improve accuracy in predicting pathologic complete response to pre-operative chemoradiotherapy in esophageal cancer. **Page 691**

^{124}I PET/CT and recurrent thyroid cancer: Kist and colleagues describe a prospective multicenter cohort study designed to test the hypothesis that ^{124}I PET/CT can identify patients who will have tumor-negative ^{131}I whole-body scintigraphy after ^{131}I therapy. **Page 701**

^{68}Ga -DOTATATE toxicity and efficacy: Deppen and colleagues evaluate the safety and efficacy of ^{68}Ga -DOTATATE PET/CT for diagnosis, staging, and restaging of pulmonary and gastroenteropancreatic neuroendocrine tumors and compare these results with those from ^{111}In -pentetreotide imaging. **Page 708**

GLP-1R PET/CT and insulinomas: Luo and colleagues compare the effectiveness of glucagon-like peptide-1 receptor PET/CT using ^{68}Ga -NOTA-exendin-4 with that of SPECT/CT, MR, and ultrasound imaging in detecting insulinoma in a prospective cohort of patients with endogenous hyperinsulinemic hypoglycemia. **Page 715**

^{18}F -FCH PET/CT repeatability: Oprea-Lager and colleagues assess the repeatability of various semiquantitative ^{18}F -fluoromethylcholine parameters in patients with histologically proven prostate cancer and lymphatic or hematogenous metastases. **Page 721**

^{18}F -FLT PET and lymphoma prognosis: Schöder and colleagues detail the abilities of ^{18}F -FLT and ^{18}F -FDG PET to predict clinical outcomes after R-CHOP-14 therapy in patients with advanced B-cell lymphoma. **Page 728**

PET prediction in Ewing sarcoma: O and colleagues detail the prognostic value of early quantitative ^{18}F -FDG PET in monitoring therapy with an antibody to the insulin-like growth factor 1 receptor in patients with Ewing sarcoma-related disease. **Page 735**

CXCR4 PET in solid cancers: Vag and colleagues report on the distribution and potential diagnostic value of a novel ^{68}Ga -labeled chemokine receptor-targeted PET probe in patients with solid cancers with in vitro evidence of CXCR4 overexpression. **Page 741**

Microfluidic preparation of ^{89}Zr -trastuzumab: Wright and colleagues describe the design and evaluation of a microfluidic reactor capable of synthesizing a single clinical dose of ^{89}Zr -labeled antibody. **Page 747**

Lean body mass on PET/CT: Decazes and colleagues evaluate the reliability of a method for estimation of lean body mass for semiquantification of ^{18}F -FDG uptake using data from low-dose CT from PET/CT acquired over standard acquisition fields. **Page 753**

Dose deposits in micrometastases: Hindié and colleagues compare the effectiveness of ^{90}Y , ^{177}Lu , ^{111}In , and ^{161}Tb in irradiating micrometastases, using the Monte Carlo code CELLDOS to assess electron doses in a range of spheres. **Page 759**

c-MET imaging of locoregional recurrence: Arulappu and colleagues assess ^{18}F -AH113804, a peptide-based molecular imaging agent with high affinity for human c-MET, in detection of

early-stage locoregional recurrence in a human basal-like breast cancer model. **Page 765**

Immuno-PET and ovarian cancer: Sharma and colleagues synthesize an ^{89}Zr -labeled monoclonal antibody targeted to CA125 and evaluate PET imaging and biodistribution in mice bearing human ovarian adenocarcinoma xenografts. **Page 771**

SV2A PET NHPs: Nabulsi and colleagues describe synthesis and characterization in nonhuman primates of a PET synaptic vesicle glycoprotein radiotracer with the potential to serve as a biomarker of synaptic density in neurodegenerative disorders. **Page 777**

^{11}C -PBR28 rat pharmacokinetics: Parente and colleagues evaluate this second-generation translocator protein tracer as a tool for detection and quantification of neuroinflammation in preclinical studies and compare its imaging properties with those of (*R*)- ^{11}C -PK11195. **Page 785**

^{18}F -THK5117 PET in transgenic mice: Brendel and colleagues visualize tau deposition in vivo with the 2-arylquinoline derivative ^{18}F -THK5117 using small-animal PET in conjunction with autoradiography and immunohistochemistry in 2 transgenic mouse models expressing hyperphosphorylated tau. **Page 792**

^{111}In -exendin-3 for islet imaging: van der Kroon and colleagues explore imaging of transplanted islets in rats with a small-animal SPECT scanner and ^{111}In -labeled exendin-3 to target the glucagon-like peptide-1 receptor expressed on β -cells. **Page 799**

Response evaluation with ^{99m}Tc -Duramycin: Elvas and colleagues report on a study designed to validate the use of ^{99m}Tc -labeled tetracycline hydrochloride for SPECT imaging of induction of cell death and early response of tumors to treatment. **Page 805**

^{89}Zr -AMG 110 PET: Warnders and colleague describe tumor targeting and tissue distribution with this radiolabeled antibody construct that induces T cell-mediated cell death by cross-linking the epithelial cell adhesion molecule with a cluster of differentiation on T cells. **Page 812**

Spatial bias in brain PET/MR: Teuho and colleagues investigate spatial bias in brain PET/MR using an anthropomorphic brain phantom in 7 PET/MR and PET/CT systems at 4 institutions. **Page 818**